Lilly's Ramucirumab Makes an Impact in Tough-To-Treat Gastric Cancer, but Will It be Enough?
SAN FRANCISCO---Eli Lilly & Co.’s VEGF inhibitor ramucirumab made an impression when it showed single agent activity in second-line gastric cancer in the REGARD study and became one of the few non-chemotherapy...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Study